Autolus Therapeutics plc (AUTL)

4.0100 -0.0700 (-1.72%) 收市：04:00PM EDT

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London W12 7FP
United Kingdom
44 20 3829 6230
https://www.autolus.com

版塊: Healthcare
行業: Biotechnology
全職員工: 463

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Christian Martin Itin Ph.D.	CEO & Director	2.41M	無	1964
Dr. Martin Pule M.D., MBBS	Founder, Senior VP & Chief Scientific Officer	無	無	1972
Mr. Robert F. Dolski	Senior VP & CFO	無	無	1971
Mr. Christopher Vann	Senior VP & COO	無	無	1965
Mr. David Brochu	Senior VP & Chief Technical Officer	無	無	1956
Mr. Alexander Swan	Senior VP & Chief Human Resources Officer	無	無	1965
Mr. Brent Rice	Senior VP, Chief Commercial Officer & Site Head of US	無	無	1966
Ms. Olivia Manser	Director of Investor Relations	無	無	無
Mr. Alex Driggs	Senior VP of Legal Affairs & General Counsel and Secretary	無	無	無
Dr. Chris Williams	Senior VP & Chief Business Development Officer	無	無	1980

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

公司管治

截至 無 止，Autolus Therapeutics plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。